288 related articles for article (PubMed ID: 32344526)
1. COVID-19 and RAS: Unravelling an Unclear Relationship.
D'Ardes D; Boccatonda A; Rossi I; Guagnano MT; Santilli F; Cipollone F; Bucci M
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32344526
[TBL] [Abstract][Full Text] [Related]
2. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
[TBL] [Abstract][Full Text] [Related]
3. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
4. Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.
Dworakowska D; Grossman AB
J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32633235
[TBL] [Abstract][Full Text] [Related]
5. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Tseng YH; Yang RC; Lu TS
Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
[TBL] [Abstract][Full Text] [Related]
6. ACE2 and COVID-19 and the resulting ARDS.
Zhang X; Li S; Niu S
Postgrad Med J; 2020 Jul; 96(1137):403-407. PubMed ID: 32522846
[TBL] [Abstract][Full Text] [Related]
7. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
8. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists.
Steckelings UM; Sumners C
Clin Sci (Lond); 2020 Nov; 134(22):2987-3006. PubMed ID: 33210709
[TBL] [Abstract][Full Text] [Related]
9. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.
South AM; Brady TM; Flynn JT
Hypertension; 2020 Jul; 76(1):16-22. PubMed ID: 32367746
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
[TBL] [Abstract][Full Text] [Related]
11. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).
Zemlin AE; Wiese OJ
Ann Clin Biochem; 2020 Sep; 57(5):339-350. PubMed ID: 32369402
[TBL] [Abstract][Full Text] [Related]
12. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
Young MJ; Clyne CD; Chapman KE
J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970
[TBL] [Abstract][Full Text] [Related]
13. Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
Vitiello A; Ferrara F
Eur J Pharmacol; 2020 Sep; 883():173373. PubMed ID: 32679185
[TBL] [Abstract][Full Text] [Related]
14. Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.
Sparks MA; South A; Welling P; Luther JM; Cohen J; Byrd JB; Burrell LM; Batlle D; Tomlinson L; Bhalla V; Rheault MN; Soler MJ; Swaminathan S; Hiremath S
Clin J Am Soc Nephrol; 2020 May; 15(5):714-716. PubMed ID: 32220930
[No Abstract] [Full Text] [Related]
15. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Cadegiani FA; Goren A; Wambier CG
Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
[TBL] [Abstract][Full Text] [Related]
16. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
[TBL] [Abstract][Full Text] [Related]
17. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
Danser AHJ; Epstein M; Batlle D
Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19.
Hooper NM; Lambert DW; Turner AJ
Clin Sci (Lond); 2020 Sep; 134(18):2489-2501. PubMed ID: 32990314
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?
Aleksova A; Ferro F; Gagno G; Cappelletto C; Santon D; Rossi M; Ippolito G; Zumla A; Beltrami AP; Sinagra G
J Intern Med; 2020 Oct; 288(4):410-421. PubMed ID: 32459372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]